Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

TORONTO -- Antibe Therapeutics Inc. (“Antibe” or the “Company” TSX: ATE, OTCQX: ATBPF) today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration (“FDA”) that otenaproxesul has been placed on clinical hold, postponing the initiation of the planned Phase II trial. Antibe expects to receive a formal Clinical Hold Letter from the FDA within 30 days outlining their rationale and further details. Read More

Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance